The term "personalized medicine" remains an overused promise to apply specific treatment plans.
Innovative approaches offer the potential for effective treatments to limited target areas with improved side effect profiles.
A phase 3 trial has found pazopanib (Votrient) and sunitinib (Sutent) are both equally effective for treating metastatic kidney cancer.
Study shows it can provide durable oncologic control with a low risk of tumor recurrence.
Risk is not eliminated if patients have risk factors for chronic kidney disease, such as hypertension and diabetes.
Only 17% and 20% of patients undergoing radical or partial nephrectomy, respectively, had a renal mass biopsy in advance of surgery.
Increment in renal parenchymal volume occurs within days after a kidney is removed from a living donor.
Technique provides a tissue diagnosis in 88% of cases, according to a study.
Data support the use of percutaneous cryoablation and radiofrequency ablation for small renal tumors.
In a small study, researchers show that ultrasound-guided transhepatic radiofrequency ablation is technically feasible.
Increasing health insurance coverage and access to usual source of care necessary to meet targets.
Researchers find a 23% increased risk of death among patients who received a transfusion during surgery or post-operative hospitalization.
Increased perinephric fat is associated with increased blood loss and operative time, study shows.
The estimated recurrence rate at 10 years was 88.3%, data show.
Seventeen percent of Americans think that there is nothing people can do to change their risk.
Benefits in cancer-linked symptoms mediated by lower Impact of Event Scale one month after intervention.
Diabetes also found to increase cancer-specific mortality in patients with clear cell renal cell carcinoma.
ACE inhibitors and angiotensin receptor blockers were shown to prolong median overall survival by nine months.
